Colorectal cancer is one of the most common cancers worldwide. Traditionally, doctors have relied on tumor staging systems (such as TNM) to predict outcomes and guide treatment.
However, recent research highlights a new and powerful tool:
The Immunoscore
A recent review involving international research contributions, including work from Hôtel-Dieu de France, explores how this approach is changing the way colorectal cancer is understood and treated.
What Is the Immunoscore?
The Immunoscore is a method that evaluates how the body’s immune system interacts with a tumor.
Instead of focusing only on the tumor itself, it measures:
• The presence of immune cells (especially T-cells)
• Their density within the tumor
• Their distribution around the tumor
This provides insight into how the body is responding to cancer.
Why Is This Important?
Not all tumors behave the same, even if they appear similar on imaging or pathology.
The Immunoscore helps identify:
• Patients at higher risk of recurrence
• Patients with better or worse prognosis
• Patients more likely to respond to treatment
In many cases, it has been shown to predict outcomes more accurately than traditional staging alone.
How It Changes Treatment Decisions
One of the key advantages of the Immunoscore is its role in personalized medicine.
It can help guide decisions such as:
• Whether additional treatment (chemotherapy) is needed
• Whether a patient may benefit from immunotherapy
• How closely a patient should be monitored
Immunotherapy and the Immune Response
The Immunoscore is particularly relevant in the era of immunotherapy, where treatment targets the immune system rather than the tumor directly.
Studies show that:
Patients with higher immune activity within the tumor tend to respond better to immunotherapy treatments.
Beyond Colorectal Cancer
Although initially developed for colorectal cancer, the Immunoscore concept is now being explored in other types of cancer.
It represents a broader shift in oncology:
From “tumor-centered” to “immune-centered” cancer evaluation
Limitations and Ongoing Research
While promising, the Immunoscore is still evolving.
Challenges include:
• Cost and accessibility
• Standardization across hospitals
• Integration into routine clinical practice
New developments, including artificial intelligence and digital pathology, are expected to improve its accuracy and usability in the future.
Takeaway
The Immunoscore represents a major step toward more precise and personalized cancer care.
Instead of looking only at the tumor, it helps doctors understand:
How the body is fighting the disease.
For patients diagnosed with colorectal conditions, individualized evaluation remains essential.
